The latest price target for Lifecore Biomedical (NASDAQ:LFCR) was reported by Stephens & Co. on January 3, 2025. The analyst firm set a price target for $6.00 expecting LFCR to fall to within 12 months (a possible -7.41% downside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Lifecore Biomedical (NASDAQ:LFCR) was provided by Stephens & Co., and Lifecore Biomedical reiterated their equal-weight rating.

There is no last upgrade for Lifecore Biomedical

The last downgrade for Lifecore Biomedical Inc happened on August 28, 2024 when Barrington Research changed their price target from N/A to N/A for Lifecore Biomedical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lifecore Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lifecore Biomedical was filed on January 3, 2025 so you should expect the next rating to be made available sometime around January 3, 2026.

While ratings are subjective and will change, the latest Lifecore Biomedical (LFCR) rating was a reiterated with a price target of $6.00 to $6.00. The current price Lifecore Biomedical (LFCR) is trading at is $6.48, which is out of the analyst’s predicted range.